Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer

The purpose of this study is to learn about the safety and tolerability of Cirtuvivint in combination with Olaparib in platinum resistant ovarian cancer. The study also aims to determine the recommended dose of the combination therapy. If a participant is a good fit for the study, and they enroll in the study, they will: * Visit the clinic often at the beginning of the study for physical exams, blood draws, vital signs, and other study and routine care procedures. After the first two months participants will visit the clinic every 28 days. * Take the study medications, Cirtuvivint and Olapar

Trial Details

NCT ID
NCT06856499
Phase
PHASE1
Sponsor
University of Colorado, Denver
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • Cirtuvivint
  • Olaparib
Locations (sample)
  • Aurora, Colorado, United States|39.72943,-104.83192
  • Aurora, Colorado, United States|39.72943,-104.83192

Key Eligibility Criteria

  • Provision to sign and date the consent form.
  • Stated willingness to comply with all study procedures and be available for the duration of the study.
  • Woman aged ≥18 years of age
  • Patients must have an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 1 or 2

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →